Serum Resistin as a Biomarker in Nonalcoholic Fatty Liver Disease: Is This a Road to be Taken?
Open Access
- 3 August 2021
- journal article
- editorial
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000), 000
- https://doi.org/10.14218/jcth.2021.00236
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysisThe Lancet Gastroenterology & Hepatology, 2020
- Obstructive sleep apnea, chronic obstructive pulmonary disease and NAFLD: an individual participant data meta-analysisSleep Medicine, 2020
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementJournal of Hepatology, 2020
- Resistin as a predictor of cardiovascular hospital admissions and renal deterioration in diabetic patients with chronic kidney diseaseJournal of Diabetes and its Complications, 2019
- Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adultsBMJ, 2019
- Association between non‐alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta‐analysisLiver International, 2019
- Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysisDiabetes Care, 2018
- Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysisJournal of Hepatology, 2016
- Resistin and Insulin Resistance: A Link Between Inflammation and HepatocarcinogenesisAsian Pacific Journal of Cancer Prevention, 2015
- Association between Resistin Levels and All-Cause and Cardiovascular Mortality: A New Study and a Systematic Review and Meta-AnalysisPLOS ONE, 2015